Search Results - kibem+kim

2 Results Sort By:
Targeting of Myeloid-Derived Suppressor Cells (MDSCs) for Cancer Treatment
Value Proposition·      Addresses key resistance mechanism: targets MDSCs, a central driver of resistance to immune checkpoint inhibitors in metastatic and poorly immunogenic cancers·      Synergistic combination strategy: Combines epigenetic modulators (HDAC and DNA methyltransferase inhibitors) with anti-PD-1 and anti-CTLA-4 antibodies to restore...
Published: 3/12/2026   |   Inventor(s): KiBem Kim, Bert Vogelstein, Kenneth Kinzler, Shibin Zhou
Keywords(s): Antagonists/Inhibitors, Antibodies, Biologics, Cancers, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities
Use of Bacteria, Bacterial Products, and other Immunoregulatory Entities in Combination with Anti-CTLA-4 and/or Anti-PD-1 Antibodies to Treat Solid Tumor Malignancies
Combined Therapeutic Method for Solid TumorJHU REF: [C12570]Invention novelty: This technology is a combination therapy method including a tumor-specific bacterium and antibodies that boost tumor immune response.Value PropositionWorldwide cancer affects more than 12 million people each year. This number is expected to increase to 14 million each year...
Published: 3/12/2026   |   Inventor(s): Kenneth Kinzler, Bert Vogelstein, KiBem Kim, Shibin Zhou
Keywords(s): Antibodies, Biologics, Cancers, Combination, Disease Indication, Immunotherapy/ Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Whole cell
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Immunotherapies
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum